Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated July 8, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 66,000 people across 80 countries. The filing specifically details transactions executed under a sub-programme initiated on May 6, 2024, within a broader 12-month repurchase plan.
Key Financial Metrics
The filing focuses on capital allocation via share buybacks rather than operational financial performance. Key metrics include:
- Total Repurchase Programme Cap: Up to DKK 20 billion over a 12-month period starting February 6, 2024.
- Sub-Programme Cap (May-August 2024): Up to DKK 2.2 billion.
- Cumulative Repurchases (Feb 6 - July 5, 2024): 10,246,595 B shares purchased for a total value of DKK 8,970,451,933.
- Average Purchase Price (Cumulative): DKK 875.46 per B share.
- Treasury Shares Held: 11,612,159 B shares, representing 0.3% of total share capital.
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
Material Changes and Recent Activity
Since the last announcement on July 1, 2024, the company executed repurchases on five consecutive trading days (July 1 through July 5). The specific activity during this period included:
- July 1: 36,500 shares at DKK 1,000.38 (Value: DKK 36,513,702).
- July 2: 41,500 shares at DKK 996.38 (Value: DKK 41,349,738).
- July 3: 39,000 shares at DKK 979.48 (Value: DKK 38,199,570).
- July 4: 34,000 shares at DKK 968.79 (Value: DKK 32,938,742).
- July 5: 33,970 shares at DKK 973.80 (Value: DKK 33,080,012).
Accumulated transactions under the specific May-August sub-programme reached 1,512,345 shares with a total value of DKK 1,442,717,161 as of July 5, 2024.
Guidance, Outlook, and Risks
Novo Nordisk expects to continue repurchasing B shares up to the DKK 20 billion limit during the 12-month period beginning February 6, 2024. The programme is conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules. The filing does not provide specific operational guidance, revenue forecasts, or discuss new material risks beyond the standard execution of the buyback programme.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 20 billion total programme (approx. DKK 11.03 billion remaining as of July 5).
- Confirm the current market price of B shares relative to the recent average purchase price of DKK 970-1,000.
- Review the company's full annual report (Form 20-F) for comprehensive revenue, profit, and cash flow data, as this filing contains only treasury stock activity.
- Monitor the Nasdaq Copenhagen (Novo-B) and NYSE (NVO) listings for further transaction disclosures.